Skip to main content

Day: February 6, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET. A live webcast will be available under the Events section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of...

Continue reading

Company Clears All Outstanding Cashless Warrants from December Capital Raise

Investors From December $9.5 Million Public Offering Exercise All Outstanding Series B Warrants Fort Lauderdale, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME), an AI-driven technology and consumer electronics holding company, today announced that all outstanding Series B cashless warrants have been fully exercised. These warrants were issued in connection with a public offering that closed on December 4, 2024. As part of that transaction, the Company entered into a securities purchase agreement (the “Purchase Agreement”) related to the public offering of 4,200,000 shares of its common stock, par value $0.01 per share (“Common Stock”), and 51,682,352 Pre-Funded Warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares of Common Stock. Pursuant to the...

Continue reading

Dragonfly Energy Appoints AdvisIRy Partners as its Investor Relations Firm

RENO, Nev., Feb. 06, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and battery technology, today announced it has appointed AdvisIRy Partners as its new investor relations firm. Chief Executive Officer, Dr. Denis Phares, stated, “Dragonfly Energy is an industry leader in providing innovative lithium-ion battery solutions across the RV, trucking, and industrial sectors. The Company is also working to revolutionize next generation battery cell manufacturing with our proprietary dry electrode technology. With Dragonfly Energy at a pivotal point in our evolution, we are pleased to partner with AdvisIRy Partners to help strengthen our investor relations program and communicate our vision and future prospects.” AdvisIRy...

Continue reading

ZenaTech’s ZenaDrone Starts Testing its High-Density Batteries to Extend Flight Time for ZenaDrone 1000 Drone for US Defense Applications

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that ZenaDrone will commence testing work this quarter on a high density battery for the ZenaDrone 1000 multifunction AI drone designed for defense and commercial applications. High density batteries are lightweight and enable longer drone flight times, more reliability and endurance for longer defense missions, heavier payloads, and greater operational success of a wide range of military applications. ZenaDrone will use the batteries from ZenaTech’s affiliated company Galaxy Batteries Inc. “High density batteries are key to longer flight...

Continue reading

Capital Clean Energy Carriers Corp. Announces Fourth Quarter 2024 Financial Results

ATHENS, Greece, Feb. 06, 2025 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (the “Company,” “CCEC” or “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today released its financial results for the fourth quarter ended December 31, 2024. Key Quarterly HighlightsAnnounced dividend of $0.15 for the fourth quarter of 2024 Concluded the sale of three debt-free container sister vesselsIn November 2023, the Company announced its decision to shift its strategic focus towards the transportation of various forms of gas to industrial customers, including liquefied natural gas (“LNG”) and new commodities emerging in connection with the energy transition. As a result, the Company agreed to acquire 11 newbuild LNG carriers (“LNG/C”) (the “Newbuild LNG/C Vessels”) and in June 2024, the Company further invested...

Continue reading

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) — BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to $10 million USD in capital and explore an initial public offering on a major US public exchange, subject to requisite regulatory approval. Quantum BioPharma Ltd. retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition www.unbuzzd.com. The agreement...

Continue reading

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a new potential first line treatment option for TS Sepranolone (isoallopregnanolone) is a first-in-class compound from new subgroup of neurosteroids known as GAMSAs- GABAA Modulating Steroid Antagonists – acting selectively on the GABAA pathway, potentially alleviating the negative effect of Allopregnanolone in Tourette syndrome and other compulsive disorders CORAL GABLES, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the...

Continue reading

VR Resources Provides Exploration Update on Silverback and Empire Projects, Ontario

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) — VR Resources Ltd. (TSX.V: VRR, FSE: 5VR; OTCQB: VRRCF), the “Company“, or “VR“, is pleased to provide an update on its ongoing exploration activities at the Silverback and Empire projects in northwestern Ontario.Two holes are complete and third underway at Silverback, covering 700 metres of strike along the CZ target; Data from the down-hole EM survey at the Westwood target at the Empire Project has arrived, and we expect all remaining geochemical data from the December drill program next week.Justin Daley, CEO of VR Resources, stated, “The crew and rig at Silverback are fully in gear now, and we are genuinely excited about what the first two holes are showing us. As described in the bullets below, the geological observations so far...

Continue reading

Washington Metropolitan Area Transit Authority awards contract to NFI subsidiary New Flyer for up to 500 low- and zero-emission Xcelsior® buses

         ST. CLOUD, Minn., Feb. 06, 2025 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI) a leading independent bus and coach manufacturer and a leader in zero-emission electric mass mobility solutions, subsidiary New Flyer of America Inc. (New Flyer), today announced a significant contract award for a mix of zero-emission (ZEBs) and hybrid buses with the Washington Metropolitan Area Transit Authority (Metro). The contract encompasses up to 500 buses, adding to New Flyer’s robust fourth-quarter 2024 backlog. This includes a firm order for 75 Xcelsior® hybrid-electric 40-foot transit buses and 25 Xcelsior CHARGE NG™ 35-foot battery-electric buses, and options for up to 400 additional buses. Metro provides Metrorail and Metrobus transit services for more than six million people across the National...

Continue reading

First National Corporation Reports Fourth Quarter and Annual 2024 Financial Results

STRASBURG, Va., Feb. 06, 2025 (GLOBE NEWSWIRE) — First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported an unaudited consolidated net loss of $933 thousand and basic and diluted loss per common share of $0.10 for the fourth quarter of 2024, and adjusted operating earnings(1) of $6.0 million and adjusted operating basic and diluted earnings(1) per common share of $0.66 for the fourth quarter of 2024. For the year ended December 31, 2024, the Company reported unaudited consolidated earnings of $7.0 million and basic and diluted earnings per common share of $1.00 and adjusted operating earnings(1) of $14.6 million and adjusted basic and diluted earnings per common share(1) of $2.10 for the year ended December 31, 2024. “2024 was a transformational...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.